Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events ...
Tag: lenvatinib
Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy
1. The median progression-free survival and overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy. 2. Clinically important ...
#VisualAbstract: Lenvatinib plus pembrolizumab improves overall survival and progression free survival for advanced renal cell carcinoma treatment
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
Lenvatinib plus pembrolizumab for advanced renal cell carcinoma treatment
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...